Evidence map›Paper›PMID 34622927›Full record

ArticleThe Biochemical journal2021

IFIT3 (interferon induced protein with tetratricopeptide repeats 3) modulates STAT1 expression in small extracellular vesicles.

Nicole M Naranjo, Israa Salem, Maisha A Harris, Lucia R Languino

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Small extracellular vesicle-mediatedCancer biology & therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicole M NaranjoProstate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Israa SalemProstate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Maisha A HarrisProstate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
Lucia R LanguinoProstate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.ORCID 0000-0001-9011-7031
Thomas Jefferson University · US

Funding

Role of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2M
Integrin-mediated mechanisms of prostate cancer progressionR01CA224769 · NCI · THOMAS JEFFERSON UNIVERSITY · PI LANGUINO, LUCIA R. · 2018 to 2022
$2.0M
NCI NIH HHS P01 CA140043NCI NIH HHS R01 CA224769
6 · The paper itself

Abstract

We have previously shown that the αvβ6 integrin plays a key role in promoting prostate cancer (PrCa) and it can be transferred to recipient cells via small extracellular vesicles (sEVs). Furthermore, we have reported in a proteomic analysis that αvβ6 integrin down-regulation increases the expression of IFIT3 (interferon induced protein with tetratricopeptide repeats 3) in PrCa cells and their derived sEVs. IFIT3 is a protein well known for being an antiviral effector, but recently its role in cancer has also been elucidated. To study the relationship between IFIT3 and STAT1 (signal transducer and activator of transcription 1), an upstream regulator of IFIT3, in PrCa cells and their released sEVs, we used CRISPR/Cas9 techniques to down-regulate the expression of the β6 integrin subunit, IFIT3 or STAT1. Our results show that IFIT3 and STAT1 are highly expressed in PrCa cells devoid of the β6 integrin subunit. However, IFIT3 but not STAT1, is present in sEVs derived from PrCa cells lacking the β6 integrin subunit. We demonstrate that loss of IFIT3 generates sEVs enriched in STAT1 but reduces the levels of STAT1 in the cells. As expected, IFIT3 is not detectable in STAT1 negative cells or sEVs. We thus propose that the observed STAT1 enrichment in sEVs is a compensatory mechanism for the loss of IFIT3. Overall, these results provide new insights into the intrinsic role of IFIT3 as a regulator of STAT1 expression in sEVs and in intercellular communication in PrCa.

Indexed as

Cell Line, TumorExtracellular VesiclesHumansIntracellular Signaling Peptides and ProteinsMaleProstatic NeoplasmsSTAT1 Transcription FactorIFIT3 protein, humanIntracellular Signaling Peptides and ProteinsSTAT1 protein, humanSTAT1 Transcription FactorIFIT3interferon-stimulated genesprostate cancersmall extracellular vesiclesSTAT1αvβ6 integrin

Identifiers

PMID34622927
PMCPMC9121857
OpenAlexW3202047986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.